Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03381261 · ClinicalTrials.gov registry record · Phase 4
(Botox) Mechanisms of Action in Altering the Molecular Environment in Which Pain Fibers Exist
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 37
- Enrollment target
NCT03381261: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT03381261 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 37 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03381261, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 37 participants
- Enrollment target
Study Summary
To compare Botox-treated and Botox-untreated symptomatic tissues (defined as areas where the head hurts and the pain is felt) of chronic migraine (CM) patients using molecular studies.
Interventions
- DRUG Botulinum toxin type A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2023-12-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03381261
The ClinicalTrials.gov registry entry for NCT03381261 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Botulinum toxin type A is the first listed.
NCT03381261 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03381261 about?
NCT03381261 is a clinical study titled "(Botox) Mechanisms of Action in Altering the Molecular Environment in Which Pain Fibers Exist". To compare Botox-treated and Botox-untreated symptomatic tissues (defined as areas where the head hurts and the pain is felt) of chronic migraine (CM) patients using molecular studies.
What is the current status of trial NCT03381261?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 37 participants. The study started on 2017-12-01. Estimated completion is 2023-12-01.
What interventions are being tested in trial NCT03381261?
The interventions under investigation include: Botulinum toxin type A (DRUG).
Who is sponsoring clinical trial NCT03381261?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.